A list of 20 largest U.S. healthcare mergers and acquisitions announced in 2012, ranked by completed or pending deal's price. Source: Modern Healthcare's 2012 Healthcare M&A Watch series; WNS Global Services. Published Jan. 28, 2013, p. 42.

Read the full story: http://bit.ly/VzsvW6

Source: ModernHealthcare.com

Related Content

Poor air quality. | Image Credit: tonjung- stock.adobe.com

May 24th 2025

Skin Diseases and Aging Linked to Air Pollution

Cameron Santoro

Air pollution significantly contributes to and worsens various dermatologic conditions through oxidative stress, inflammation, and disruption of the skin barrier.

May 20th 2025

Mental Health Awareness: Transforming Workplace Support and Engagement

Giuliana Grossi Jim Kinville

Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.

May 23rd 2025

News Reports on Biden’s Prostate Cancer Reflect Controversy, Limits of PSA Testing

Mary Caffrey

Following former President Joe Biden's diagnosis with metastatic prostate cancer, news coverage has focused on his lack of prostate-specific antigen (PSA) screening over the past decade.

May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS

Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.

Based on western blot testing, patients who received gene therapy at 2 years old showed a mean dystrophin expression of 93.87% of normal. | Image Credit: Treecha - stock.adobe.com

May 23rd 2025

DMD Gene Therapy Shows Efficacy, Safety in Patients Treated at 2 Years Old

Rose McNulty

Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a favorable safety profile in young patients.

Crohn's disease and guselkumab | Image credit: New Africa - stock.adobe.com

May 23rd 2025

Guselkumab Demonstrates Rapid and Lasting Results in Crohn Disease

Guselkumab shows significant clinical and endoscopic benefits for adults with moderate to severe Crohn disease, offering a promising treatment alternative.

Related Content

May 24th 2025

Skin Diseases and Aging Linked to Air Pollution

Cameron Santoro

Air pollution significantly contributes to and worsens various dermatologic conditions through oxidative stress, inflammation, and disruption of the skin barrier.

May 20th 2025

Mental Health Awareness: Transforming Workplace Support and Engagement

Giuliana Grossi Jim Kinville

May 23rd 2025

News Reports on Biden’s Prostate Cancer Reflect Controversy, Limits of PSA Testing

Mary Caffrey

Following former President Joe Biden's diagnosis with metastatic prostate cancer, news coverage has focused on his lack of prostate-specific antigen (PSA) screening over the past decade.

May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS

May 23rd 2025

DMD Gene Therapy Shows Efficacy, Safety in Patients Treated at 2 Years Old

Rose McNulty

Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a favorable safety profile in young patients.

May 23rd 2025

Guselkumab Demonstrates Rapid and Lasting Results in Crohn Disease

Guselkumab shows significant clinical and endoscopic benefits for adults with moderate to severe Crohn disease, offering a promising treatment alternative.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions